A Randomised, Double-Masked, Placebo-Controlled Phase 3 Study on the Efficacy and Safety of STN1013800 (Oxymetazoline HCl 0.1% Eye Drops) used twice daily (BID) in the Treatment of Acquired Blepharoptosis
Phase 3 – large-scale trial before approval
Conditions:
Acquired Blepharoptosis
Sponsor: Santen
trial.available_in:
БГ
Overview
Trial status: Authorised
PRO: PGIC on Day 14
Change from baseline in MRD1 on Day 14
Description
PRO: PGIC on Day 14
Who can participate
Age group: 18-64 years, 65+ years
Gender: Female, Male
Target enrollment: 291 participants
БГ